Galapagos and Celera Genomics sign gene function analysis agreement

21-Jun-2005

Galapagos announced that it has entered into a services agreement with Celera Genomics Group, an Applera Corporation business. Under the agreement, Galapagos' services division Galadeno will provide technology and adenoviral reagents enabling Celera to analyze gene function in human cells and validate potential drug targets. Galadeno will receive payments related to its services and technology.

Under the terms of the agreement, Galadeno will construct recombinant adenoviruses harboring genes selected by Celera. These custom-made viruses will be used to introduce the genes into various cell types to evaluate their function within biological pathways.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances